Related Experiment Videos
Deutetrabenazine for the treatment of Huntington's chorea
Hassaan Bashir1, Joseph Jankovic1
1a Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology , Baylor College of Medicine , Houston , TX , 77030-4202 , USA.
Insights
Deutetrabenazine offers a promising new symptomatic treatment for chorea in Huntington's disease (HD). This vesicular monoamine transporter type 2 (VMAT2) inhibitor shows comparable efficacy to tetrabenazine with potentially fewer adverse effects.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Huntington's disease (HD) is an inherited neurodegenerative disorder with no current disease-modifying treatments.
- Chorea, a common motor symptom of HD, significantly impacts daily activities and quality of life.
- Current treatment options for HD chorea are limited to symptomatic relief.
Purpose of the Study:
- To review the pharmacological properties, clinical efficacy, and tolerability of deutetrabenazine for treating chorea in Huntington's disease.
- To compare deutetrabenazine with tetrabenazine, a previously approved vesicular monoamine transporter type 2 (VMAT2) inhibitor.
- To assess the expanding role of VMAT2 inhibitors in managing hyperkinetic movement disorders.
Main Methods:
- Literature review based on a detailed PubMed search.
- Analysis of pharmacological and pharmacokinetic data for deutetrabenazine.
- Evaluation of clinical trial data on the efficacy and safety of deutetrabenazine in HD patients.
Main Results:
- Deutetrabenazine is the first deuterated drug and second VMAT2 inhibitor approved for HD chorea.
- Pharmacological and pharmacokinetic differences suggest deutetrabenazine may be as effective as tetrabenazine.
- Deutetrabenazine demonstrates a potentially lower risk of adverse effects compared to tetrabenazine.
Conclusions:
- Deutetrabenazine presents a promising therapeutic option for managing chorea associated with Huntington's disease.
- VMAT2 inhibitors, including deutetrabenazine, are increasingly important in treating hyperkinetic movement disorders due to their efficacy and favorable tolerability.
- Further research may solidify the role of deutetrabenazine in improving the quality of life for HD patients.
Introduction:
Huntington's disease (HD) is an inherited neurodegenerative disorder for which no disease-modifying treatment is currently available. Only symptomatic treatment can be offered. Chorea is the most common motor manifestation of HD and may interfere with daily activities, reduce quality of life, and cause injury. Areas covered: Deutetrabenazine is the first deuterated drug and second drug after tetrabenazine, the classic vesicular monoamine transporter type 2 (VMAT2) inhibitor, to receive approval for the treatment of chorea associated with HD. This review, based largely on a detailed PubMed search, will summarize the pharmacological properties, clinical evidence of efficacy and tolerability of deutetrabenazine in the treatment of HD chorea. Expert commentary: Due to differences in pharmacology and pharmacokinetics, deutetrabenazine has shown promise that it is at least as effective as tetrabenazine in the treatment of HD chorea but has a lower risk of adverse effects. The role of VMAT2 inhibitors in the treatment of hyperkinetic movement disorders is expanding due to their efficacy and favorable tolerability profiles.